Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
SACHS BRUCE I | Director | Jan 31 | Option Exercise | 72.14 | 1,200 | 86,568 | 42,410 | Feb 02 04:14 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Jan 31 | Sale | 325.00 | 106 | 34,450 | 37,998 | Feb 02 04:18 PM | SACHS BRUCE I | Director | Jan 31 | Sale | 325.01 | 1,200 | 390,012 | 41,210 | Feb 02 04:14 PM | CARNEY LLOYD | Director | Jan 30 | Sale | 320.52 | 2,700 | 865,406 | 4,150 | Jan 31 04:45 PM | Lee Yuchun | Director | Jan 27 | Option Exercise | 72.14 | 1,429 | 103,088 | 3,304 | Jan 31 04:42 PM | Lee Yuchun | Director | Jan 27 | Sale | 322.03 | 1,429 | 460,177 | 1,875 | Jan 31 04:42 PM | Lee Yuchun | Director | Jan 26 | Option Exercise | 72.14 | 4,000 | 288,560 | 5,875 | Jan 27 04:18 PM | Lee Yuchun | Director | Jan 26 | Sale | 318.33 | 4,000 | 1,273,322 | 1,875 | Jan 27 04:18 PM | Lee Yuchun | Director | Jan 25 | Option Exercise | 72.14 | 4,000 | 288,560 | 5,875 | Jan 27 04:18 PM | Lee Yuchun | Director | Jan 25 | Sale | 313.96 | 4,000 | 1,255,852 | 1,875 | Jan 27 04:18 PM | Kewalramani Reshma | CEO & President | Jan 25 | Sale | 315.05 | 10,000 | 3,150,500 | 89,598 | Jan 27 04:13 PM | Lee Yuchun | Director | Jan 24 | Option Exercise | 72.14 | 4,000 | 288,560 | 5,875 | Jan 25 04:08 PM | Lee Yuchun | Director | Jan 24 | Sale | 312.69 | 4,000 | 1,250,753 | 1,875 | Jan 25 04:08 PM | Lee Yuchun | Director | Jan 23 | Option Exercise | 72.14 | 2,129 | 153,586 | 4,004 | Jan 25 04:08 PM | Lee Yuchun | Director | Jan 23 | Sale | 312.02 | 2,129 | 664,291 | 1,875 | Jan 25 04:08 PM | Lee Yuchun | Director | Jan 18 | Option Exercise | 72.14 | 442 | 31,886 | 2,317 | Jan 19 04:07 PM | Lee Yuchun | Director | Jan 18 | Sale | 312.17 | 442 | 137,979 | 1,875 | Jan 19 04:07 PM | Lee Yuchun | Director | Jan 17 | Option Exercise | 72.14 | 4,000 | 288,560 | 5,875 | Jan 19 04:07 PM | Lee Yuchun | Director | Jan 17 | Sale | 312.03 | 4,000 | 1,248,120 | 1,875 | Jan 19 04:07 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Nov 15 | Sale | 308.61 | 34 | 10,493 | 36,077 | Nov 17 04:08 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Nov 07 | Option Exercise | 187.53 | 1,303 | 244,352 | 37,380 | Nov 09 04:40 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Nov 07 | Sale | 303.04 | 1,303 | 394,859 | 36,077 | Nov 09 04:40 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Nov 02 | Sale | 312.64 | 320 | 100,045 | 38,104 | Nov 03 04:05 PM | Bhatia Sangeeta N. | Director | Oct 24 | Sale | 310.00 | 621 | 192,510 | 4,040 | Oct 26 04:05 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Oct 18 | Sale | 300.31 | 1,791 | 537,860 | 39,192 | Oct 20 04:11 PM | Arbuckle Stuart A | EVP, COO | Aug 15 | Option Exercise | 155.57 | 6,571 | 1,022,250 | 67,451 | Aug 17 05:39 PM | Liu Joy | SVP, General Counsel | Aug 15 | Sale | 303.90 | 3,747 | 1,138,723 | 9,605 | Aug 17 05:36 PM | Kewalramani Reshma | CEO & President | Aug 15 | Sale | 305.06 | 11,689 | 3,565,846 | 99,598 | Aug 17 05:40 PM | Arbuckle Stuart A | EVP, COO | Aug 15 | Sale | 303.93 | 22,173 | 6,738,991 | 45,278 | Aug 17 05:39 PM | Arbuckle Stuart A | EVP, COO | Aug 10 | Option Exercise | 155.57 | 64 | 9,956 | 61,060 | Aug 12 04:05 PM | Arbuckle Stuart A | EVP, COO | Aug 10 | Sale | 300.40 | 180 | 54,073 | 60,880 | Aug 12 04:05 PM | Liu Joy | SVP, General Counsel | Aug 10 | Sale | 300.32 | 36 | 10,812 | 13,352 | Aug 12 04:05 PM | Arbuckle Stuart A | EVP, COO | Aug 09 | Option Exercise | 155.57 | 1,926 | 299,628 | 66,686 | Aug 10 04:06 PM | Liu Joy | SVP, General Counsel | Aug 09 | Sale | 300.00 | 946 | 283,800 | 13,388 | Aug 10 04:06 PM | Arbuckle Stuart A | EVP, COO | Aug 09 | Sale | 300.67 | 5,690 | 1,710,817 | 60,996 | Aug 10 04:06 PM | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Aug 09 | Sale | 298.97 | 1,400 | 418,557 | 46,090 | Aug 10 04:06 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Aug 08 | Option Exercise | 187.53 | 1,304 | 244,539 | 37,381 | Aug 10 04:06 PM | Bhatia Sangeeta N. | Director | Aug 08 | Sale | 293.03 | 621 | 181,972 | 4,661 | Aug 10 04:07 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Aug 08 | Sale | 292.54 | 1,304 | 381,469 | 36,077 | Aug 10 04:06 PM | Bhatia Sangeeta N. | Director | Jul 29 | Sale | 278.77 | 621 | 173,116 | 5,282 | Aug 02 04:16 PM | LEIDEN JEFFREY M | Executive Chairman | Jul 25 | Option Exercise | 91.05 | 60,342 | 5,494,139 | 134,502 | Jul 27 04:17 PM | LEIDEN JEFFREY M | Executive Chairman | Jul 25 | Sale | 281.38 | 132,079 | 37,164,481 | 2,423 | Jul 27 04:17 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Jul 19 | Option Exercise | 174.33 | 17,765 | 3,096,948 | 53,942 | Jul 21 04:48 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Jul 19 | Sale | 288.65 | 17,865 | 5,156,730 | 36,077 | Jul 21 04:48 PM | Kewalramani Reshma | CEO & President | Jun 24 | Sale | 291.30 | 11,689 | 3,405,006 | 111,153 | Jun 28 04:05 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | May 16 | Sale | 252.83 | 45 | 11,377 | 41,749 | May 18 04:22 PM | Arbuckle Stuart A | EVP, COO | May 16 | Sale | 251.19 | 133 | 33,408 | 64,760 | May 18 04:21 PM | Liu Joy | SVP, General Counsel | May 16 | Sale | 252.88 | 133 | 33,633 | 14,334 | May 18 04:18 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | May 04 | Sale | 275.09 | 36 | 9,903 | 41,660 | May 06 04:05 PM | Arbuckle Stuart A | EVP, COO | May 02 | Sale | 263.98 | 306 | 80,778 | 64,760 | May 04 05:21 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | May 02 | Sale | 259.16 | 320 | 82,930 | 41,696 | May 04 05:10 PM | Bhatia Sangeeta N. | Director | May 02 | Sale | 258.94 | 737 | 190,842 | 5,903 | May 04 05:09 PM | WAGNER CHARLES F JR | EVP & Chief Financial Officer | May 02 | Sale | 258.83 | 343 | 88,778 | 42,730 | May 04 05:07 PM | Liu Joy | SVP, General Counsel | Apr 29 | Sale | 275.41 | 120 | 33,049 | 14,334 | May 03 04:28 PM | Ambrose Kristen | SVP & Chief Accounting Officer | Apr 25 | Sale | 269.55 | 327 | 88,143 | 3,496 | Apr 27 04:05 PM | Lee Yuchun | Director | Apr 18 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 20 04:05 PM | Lee Yuchun | Director | Apr 18 | Sale | 284.23 | 2,000 | 568,467 | 1,875 | Apr 20 04:05 PM | Lee Yuchun | Director | Apr 14 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 18 04:05 PM | Lee Yuchun | Director | Apr 14 | Sale | 289.06 | 2,000 | 578,117 | 1,875 | Apr 18 04:05 PM | Lee Yuchun | Director | Apr 13 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 13 | Sale | 287.50 | 2,000 | 575,010 | 1,875 | Apr 14 04:35 PM | LEIDEN JEFFREY M | Executive Chairman | Apr 13 | Sale | 289.04 | 15,789 | 4,563,653 | 74,160 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 12 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 12 | Sale | 281.03 | 2,000 | 562,051 | 1,875 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 11 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 12 04:07 PM | Lee Yuchun | Director | Apr 11 | Sale | 280.30 | 2,000 | 560,599 | 1,875 | Apr 12 04:07 PM | MCGLYNN MARGARET G | Director | Apr 08 | Option Exercise | 127.54 | 5,000 | 637,700 | 6,099 | Apr 12 04:05 PM | Bhatia Sangeeta N. | Director | Apr 08 | Option Exercise | 125.71 | 1,907 | 239,729 | 7,098 | Apr 12 04:05 PM | Lee Yuchun | Director | Apr 08 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 12 04:07 PM | Lee Yuchun | Director | Apr 08 | Sale | 278.57 | 2,000 | 557,141 | 1,875 | Apr 12 04:07 PM | Bhatia Sangeeta N. | Director | Apr 08 | Sale | 280.20 | 1,907 | 534,341 | 5,191 | Apr 12 04:05 PM | MCGLYNN MARGARET G | Director | Apr 08 | Sale | 280.22 | 5,000 | 1,401,080 | 1,099 | Apr 12 04:05 PM | Lee Yuchun | Director | Apr 07 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 08 05:57 PM | Lee Yuchun | Director | Apr 07 | Sale | 274.86 | 2,000 | 549,720 | 1,875 | Apr 08 05:57 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Apr 07 | Sale | 276.18 | 561 | 154,935 | 42,782 | Apr 08 04:34 PM | Lee Yuchun | Director | Apr 06 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 08 05:57 PM | Lee Yuchun | Director | Apr 06 | Sale | 271.62 | 2,000 | 543,243 | 1,875 | Apr 08 05:57 PM | Lee Yuchun | Director | Apr 05 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 06 04:59 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Apr 05 | Sale | 275.23 | 3,163 | 870,552 | 43,343 | Apr 06 05:02 PM | Lee Yuchun | Director | Apr 05 | Sale | 272.50 | 2,000 | 544,993 | 1,875 | Apr 06 04:59 PM | Lee Yuchun | Director | Apr 04 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 06 04:59 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Apr 04 | Sale | 267.71 | 562 | 150,452 | 46,506 | Apr 06 05:02 PM | Lee Yuchun | Director | Apr 04 | Sale | 267.72 | 2,000 | 535,431 | 1,875 | Apr 06 04:59 PM | WAGNER CHARLES F JR | EVP & Chief Financial Officer | Apr 01 | Sale | 264.76 | 2,582 | 683,602 | 43,620 | Apr 05 04:06 PM | MCGLYNN MARGARET G | Director | Mar 31 | Option Exercise | 127.54 | 5,000 | 637,700 | 6,099 | Apr 04 04:05 PM | MCGLYNN MARGARET G | Director | Mar 31 | Sale | 262.27 | 5,000 | 1,311,346 | 1,099 | Apr 04 04:05 PM | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Mar 17 | Sale | 250.11 | 2,833 | 708,572 | 47,356 | Mar 21 04:15 PM | WAGNER CHARLES F JR | EVP & Chief Financial Officer | Mar 17 | Sale | 250.15 | 3,171 | 793,218 | 46,202 | Mar 21 04:12 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Mar 17 | Sale | 250.06 | 2,122 | 530,627 | 48,412 | Mar 21 04:10 PM | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Feb 25 | Sale | 230.95 | 325 | 75,058 | 50,189 | Feb 28 05:27 PM | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Feb 18 | Sale | 231.00 | 519 | 119,889 | 53,104 | Feb 22 05:03 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 18 | Sale | 230.97 | 4,312 | 995,949 | 49,687 | Feb 22 04:51 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 14 | Sale | 232.02 | 2,444 | 567,057 | 57,438 | Feb 16 04:05 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 11 | Sale | 235.02 | 2,297 | 539,837 | 59,882 | Feb 14 04:11 PM |
|